



**Canadian  
Cardiovascular  
Society**

**MYCOVACC**

The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre, pan-Canadian study funded by the Public Health Agency of Canada.

## \$2M Awarded to MYCOVACC for Expanding the Study of COVID-19 mRNA Vaccines

MYCOVACC has received a \$2M boost from the Public Health Agency of Canada to expand and extend follow-up on patients with myocarditis and/or pericarditis after COVID-19 mRNA immunization or COVID-19 infection, and to do cardiac imaging on those affected.

The pan-Canadian study will receive an additional two years of funding, bringing the total investment in this important initiative to \$3.6M over three years.

[Read the news release](#)

## Site Recruitment Update

MYCOVACC has recruited more than 35 study sites across Canada with the assistance of our key research partner networks.

The CCS continues to actively recruit cardiac care centres, cardiology clinics and cardiologists from across Canada to contribute to the study. [Learn more.](#)

## Stakeholder Consultations: Key Recommendations



Earlier this year, the MYCOVACC project team consulted with the cardiovascular community about their communications, knowledge translation, continuing professional development needs, and the study design.

The project team is using the guidance received from project stakeholders to:

- refine the communications and outreach plan;
- update CCS infographics on vaccine-associated myocarditis and pericarditis;
- create a new patient-facing infographic;
- revise the study protocol;
- develop continuing professional development activities that meet the needs of CCS members and other stakeholder groups including family doctors, public health, and nursing; and

- support partnerships with stakeholder groups to disseminate the study results.

Thank you to those who participated in the interviews or online survey for their valuable advice and insights.

---

## Meet the MYCOVACC Steering Committee

MYCOVACC is led by an expert Steering Committee, chaired by study leader Dr. Nathaniel Hawkins, and includes CCS members as well as representatives from key partner networks and the Public Health Agency of Canada. Read all the members' bios [here](#).



---

## Recent Research

Chassé, M., Lawler, P., Lee, D. S., McCrindle, B. W., Moayedi, Y. (Eds). Focus Issue: Advances in Understanding and Managing the Cardiovascular Complications of COVID-19. *Canadian Journal of Cardiology*. 2023 June. [https://www.onlinecjc.ca/issue/S0828-282X\(23\)X0007-5](https://www.onlinecjc.ca/issue/S0828-282X(23)X0007-5)

Reddy, P., Kane, G. C., Oh, J. K., Luis, S. A. The Evolving Etiological and Epidemiological Portrait of Pericardial Disease. *Canadian Journal of Cardiology*. 2023 May 20. <https://doi.org/10.1016/j.cjca.2023.05.011>

Yamamoto, J., Awaya, T., Nakagawa, T., Tamura, A., Hiroi, Y. Myocarditis with Ventricular Tachycardia Following Bivalent COVID-19 mRNA Vaccination. *CJC Open*. 2023 May 18. <https://doi.org/10.1016/j.cjco.2023.05.006>

---

Email: [mycovacc@ccs.ca](mailto:mycovacc@ccs.ca)

Website: <https://ccs.ca/mycovacc/>

*Financial contribution from*



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada

---



[Please click here to opt out of this mailing or to change your CCS communication preferences.](#)

Canadian Cardiovascular Society | 1000-150 Elgin Street, Ottawa, K2P 1L4 Canada

[Unsubscribe webmaster@ccs.ca](mailto:Unsubscribe.webmaster@ccs.ca)

[Constant Contact Data Notice](#)

Sent by [communications@ccs.ca](mailto:communications@ccs.ca)